News on immunohistochemistry and other tissue-based testing methods.
By uncovering genetic factors behind blood and urine biomarkers, researchers came up with polygenic scores related to biomarker status and related disease risk.
The Germany-based company is developing Molecular Cartography, a technology that offers multiplexed analysis of gene expression in tissues.
The deal joins Indivumed's collection of tissue biospecimens and immunohistochemistry expertise with Ultivue's multiplex immunofluorescence platform.
Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.
The company reported on its development of a deep learning model to predict gene expression of tumors from whole slide images without the need to sequence RNA.
